查看文章

Chronic lung disease affects> 37 million people (US); there are no treatments available to reverse the damage to airways caused by conditions such as cystic fibrosis, and primary ciliary dyskinesia. For these genetic diseases, replacing defective airway epithelial cells with autologous, gene-corrected airway stem cells could be curative. To model cell therapy, our group has successfully transplanted mouse primary or pluripotent stem cell (PSC)-derived basal cells (iBCs) into the tracheas of syngeneic recipient mice post-polidocanol (PDOC) injury. These cells durably engraft in the trachea giving rise to basal cells and differentiated airway lineages. However, minimal engraftment is seen in intrapulmonary airways. To expand this work into the intraparenchymal airways we will use a micro-bronchoscope (MB) to deliver PDOC and donor cells into the distal airways. This will allow us to study endogenous repair and the …